Stay updated on Pediatric Peanut Allergy Study with Dupilumab as Adjunct Clinical Trial

Sign up to get notified when there's something new on the Pediatric Peanut Allergy Study with Dupilumab as Adjunct Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pediatric Peanut Allergy Study with Dupilumab as Adjunct Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the study record related to Pediatric Subjects With Peanut Allergy, specifically evaluating the efficacy and safety of Dupilumab as an adjunct to AR101 in a clinical trial setting.
    Difference
    0.1%
    Check dated 2024-06-06T14:41:06.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participants, specifying the health conditions and prior treatments required for inclusion in the study. Previously, it listed the dates for the last update submissions and verifications.
    Difference
    24%
    Check dated 2024-05-22T21:11:16.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T21:59:02.000Z thumbnail image

Stay in the know with updates to Pediatric Peanut Allergy Study with Dupilumab as Adjunct Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pediatric Peanut Allergy Study with Dupilumab as Adjunct Clinical Trial page.